EWTX — Edgewise Therapeutics, Inc.
$39.31-1.70%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for EWTX in the TickerWise workspace.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 117
- Website: https://www.edgewisetx.com
Latest SEC filings for EWTX
Latest EWTX news
- Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 Read article
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.